These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38985849)

  • 21. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.
    Gray B; Van Hazel G; Hope M; Burton M; Moroz P; Anderson J; Gebski V
    Ann Oncol; 2001 Dec; 12(12):1711-20. PubMed ID: 11843249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience.
    Kim AY; Unger K; Wang H; Pishvaian MJ
    BMC Cancer; 2016 Jul; 16():492. PubMed ID: 27430276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with
    Fidelman N; Atreya CE; Griffith M; Milloy MA; Carnevale J; Cinar P; Venook AP; Van Loon K
    BMC Cancer; 2022 Dec; 22(1):1307. PubMed ID: 36514060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study.
    Maleux G; Albrecht T; Arnold D; Bargellini I; Cianni R; Helmberger T; Kolligs F; Munneke G; Peynircioglu B; Sangro B; Schaefer N; Pereira H; Zeka B; de Jong N; Bilbao JI;
    Cardiovasc Intervent Radiol; 2023 Jul; 46(7):852-867. PubMed ID: 36914788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison.
    Agirrezabal I; Bouattour M; Pinato DJ; D'Alessio A; Brennan VK; Carion PL; Shergill S; Amoury N; Vilgrain V
    Eur J Cancer; 2024 Jan; 196():113427. PubMed ID: 37988840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).
    Quartuccio N; Ialuna S; Scalisi D; D'Amato F; Barcellona MR; Bavetta MG; Fusco G; Bronte E; Musso E; Bronte F; Picciotto V; Carroccio A; Verderame F; Malizia G; Cistaro A; La Gattuta F; Moreci AM
    Curr Oncol; 2024 Mar; 31(3):1504-1514. PubMed ID: 38534947
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Jul; ():. PubMed ID: 34294586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
    Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
    Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases.
    Jia Z; Paz-Fumagalli R; Frey GT; Sella DM; McKinney JM; Wang W
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):899-905. PubMed ID: 31104533
    [No Abstract]   [Full Text] [Related]  

  • 36. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
    Gulec SA; Pennington K; Wheeler J; Barot TC; Suthar RR; Hall M; Schwartzentruber D
    Am J Clin Oncol; 2013 Oct; 36(5):455-60. PubMed ID: 22643569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis.
    Sugumar K; Stitzel H; Wu V; Bajor D; Chakrabarti S; Conces M; Henke L; Lumish M; Mahipal A; Mohamed A; Winter JM; Hardacre JM; Ammori JB; Selfridge JE; Ocuin LM
    Ann Surg Oncol; 2024 Jul; 31(7):4413-4426. PubMed ID: 38502296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.